Molecular basis of intestinal cryptosporidiosis

肠道隐孢子虫病的分子基础

基本信息

  • 批准号:
    10324243
  • 负责人:
  • 金额:
    $ 44.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-02-04 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Summary Cryptosporidium remains a significant AIDS-related opportunistic infection among people with late HIV diagnosis or without access to HAART. This parasite infects the gastrointestinal epithelium in humans; infection is also a common cause of diarrhea in young children in developing countries. There is currently no fully effective therapy available for the infection. Cryptosporidium has been referred as a “minimally invasive” mucosal pathogen, and epithelial antimicrobial defense is key to mucosal innate anti-Cryptosporidium immunity. Whereas it is well appreciated that Type II interferon-gamma (IFN-γ) is required for preventing development of intestinal cryptosporidiosis, recent advances have revealed a significant Type I IFN response (e.g., induction of IFN-alpha and IFN-beta) in host epithelium following C. parvum infection. The molecular mechanisms underlying Type I IFN response and its potential role in the pathogenesis of cryptosporidiosis are unclear. Cryptosporidium parvum virus 1 (CSpV1) is a member of the family Partitiviridae, genus Cryspovirus that infects C. parvum and other Cryptosporidium spp. Our recent studies demonstrate that host delivery of CSpV1-RNAs at the host-parasite interface can trigger a Type I IFN response in host cells. C. parvum infection attenuates intestinal epithelial cell response to IFN-γ stimulation (i.e., infected cells are less susceptible to activation by IFN-γ). Surprisingly, knockout Type I IFN signaling in intestinal epithelial cells or inhibition of CSpV1-RNA delivery can restore cellular response to IFN-γ stimulation and promotes resistance to C. parvum infection, suggesting a negative impact of Type I IFN signaling on epithelial anti-Cryptosporidium defense. Based on these observations, we hypothesize that cryptosporidial infection triggers Type I IFN response in the intestinal epithelium and attenuates IFN-γ-mediated epithelial antimicrobial defense through delivery of CSpV1- RNAs. We will use in vitro, ex vivo, and in vivo infection models and complementary biochemical, molecular, and morphologic approaches to elucidate the molecular mechanisms by which Cryptosporidium infection triggers Type I IFN gene transcription in the intestinal epithelium (Aim 1), determine how Cryptosporidium infection modulates the JAK/STAT signaling in infected intestinal epithelial cells (Aim 2), and define the impact of Cryptosporidium-induced JAK/STAT signaling dysregulation on epithelial anti-parasite defense (Aim 3). The proposal is conceptually innovative as it tests a novel mechanism for symbiotic CSpV1 in the pathogenesis of cryptosporidiosis and has the potential to inform future development of new therapeutic strategies.
摘要 在晚期HIV感染者中,隐孢子虫仍然是一种与艾滋病相关的重要机会性感染 诊断或无法访问HAART。这种寄生虫感染人类的胃肠道上皮; 感染也是发展中国家幼儿腹泻的常见原因。目前没有 对感染有完全有效的治疗方法。隐孢子虫被称为“微侵袭”。 粘膜病原体和上皮抗菌防御是粘膜天然抗隐孢子虫的关键 豁免权。鉴于众所周知,需要II型干扰素-γ(干扰素-γ)来预防 肠道隐孢子虫病的发展,最近的进展揭示了I型干扰素的显著应答 例如,在微小弧菌感染后宿主上皮细胞中诱导干扰素-α和干扰素-β。分子 I型干扰素应答的潜在机制及其在隐孢子虫病发病机制中的潜在作用 不清楚。 微小隐孢子虫病毒1 (CSpV1)是细小病毒科、隐孢子虫病毒属的一员 感染微小隐孢子虫和其他隐孢子虫。我们最近的研究表明,寄主传递的 宿主-寄生虫交界处的CSpV1-RNA可以在宿主细胞中触发I型干扰素反应。细小隐孢子虫感染 减弱肠上皮细胞对干扰素-γ刺激的反应(即,受感染的细胞对 干扰素-γ激活)。令人惊讶的是,敲除肠上皮细胞中的I型干扰素信号或抑制 CSpV1RNA可以恢复细胞对干扰素-γ刺激的反应,并促进对微小弧菌的抗性 感染,提示I型干扰素信号对上皮性抗隐孢子虫防御有负面影响。 基于这些观察结果,我们假设隐孢子虫感染会触发I型干扰素反应 CSpV1-γ介导的肠上皮细胞抗微生物防御作用 RNA。我们将使用体外,体外,体内感染模型和互补的生化,分子, 和形态学方法阐明隐孢子虫感染的分子机制 在肠道上皮细胞中触发I型干扰素基因转录(目标1),决定隐孢子虫如何 感染对感染的肠上皮细胞中JAK/STAT信号的调节(AIM 2),并确定其影响 研究隐孢子虫诱导的JAK/STAT信号异常在上皮抗寄生虫防御中的作用(目标3)。这个 该提案在概念上具有创新性,因为它测试了共生CSpV1在肺炎发病机制中的新机制。 隐孢子虫病,并有可能为未来新的治疗策略的发展提供信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xian-Ming Chen其他文献

Xian-Ming Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xian-Ming Chen', 18)}}的其他基金

Intestinal Stem Cell Responses to Cryptosporidium Infection
肠道干细胞对隐孢子虫感染的反应
  • 批准号:
    10330758
  • 财政年份:
    2020
  • 资助金额:
    $ 44.33万
  • 项目类别:
LncRNA regulation of Type I IFN signaling in intestinal epithelium
LncRNA 对肠上皮 I 型 IFN 信号传导的调节
  • 批准号:
    10321685
  • 财政年份:
    2020
  • 资助金额:
    $ 44.33万
  • 项目类别:
LncRNA regulation of Type I IFN signaling in intestinal epithelium
LncRNA 对肠上皮 I 型 IFN 信号传导的调节
  • 批准号:
    10331247
  • 财政年份:
    2020
  • 资助金额:
    $ 44.33万
  • 项目类别:
LincRNAs in Mucosal Defense to AIDS Opportunistic Pathogen Cryptosporidium
LincRNA 在粘膜防御艾滋病机会性病原体隐孢子虫中的作用
  • 批准号:
    10327943
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
LincRNAs in Mucosal Defense to AIDS Opportunistic Pathogen Cryptosporidium
LincRNA 在粘膜防御艾滋病机会病原体隐孢子虫中的作用
  • 批准号:
    10289715
  • 财政年份:
    2017
  • 资助金额:
    $ 44.33万
  • 项目类别:
Molecular basis of intestinal cryptosporidiosis
肠道隐孢子虫病的分子基础
  • 批准号:
    10359132
  • 财政年份:
    2015
  • 资助金额:
    $ 44.33万
  • 项目类别:
Molecular Basis of Intestinal Cryptosporidiosis
肠道隐孢子虫病的分子基础
  • 批准号:
    8920363
  • 财政年份:
    2015
  • 资助金额:
    $ 44.33万
  • 项目类别:
Molecular Basis of Intestinal Cryptosporidiosis
肠道隐孢子虫病的分子基础
  • 批准号:
    9419285
  • 财政年份:
    2015
  • 资助金额:
    $ 44.33万
  • 项目类别:
Molecular basis of intestinal cryptosporidiosis
肠道隐孢子虫病的分子基础
  • 批准号:
    10019152
  • 财政年份:
    2015
  • 资助金额:
    $ 44.33万
  • 项目类别:
Epithelial exosomes and TLR-mediated mucosal defense
上皮外泌体和 TLR 介导的粘膜防御
  • 批准号:
    8281423
  • 财政年份:
    2011
  • 资助金额:
    $ 44.33万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 44.33万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 44.33万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 44.33万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 44.33万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 44.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了